ストックスクリーナーアプリを入手
184.60
0.53%
-0.98
アフターアワーズ：
184.74
0.14
+0.08%
Abbvie Inc (ABBV) 最新ニュース
AbbVie Inc. (ABBV): A Bull Case Theory - MSN
AbbVie Inc. (ABBV): Among the Best Income Stocks to Invest in Now - Insider Monkey
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight - GuruFocus
Contract Research and Manufacturing Services (CRAMS) Business Report 2025: Market to Reach $211.4 Billion by 2030, Fueled by Growing Demand for Biologics and Biosimilars - GlobeNewswire Inc.
June 27th Options Now Available For AbbVie - Nasdaq
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV)June 3, 2025 Deadline to JoinContact The Gross Law Firm - Morningstar
Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks - Yahoo Finance
Are Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink? - Nasdaq
AbbVie’s Skyrizi leads pharma TV ad rankings for April - Medical Marketing and Media
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit – ABBV - TradingView
AbbVie Files Suit Challenging Tennessee’s Contract Pharmacy Law - Bloomberg Law News
Advanced Renal Cell Carcinoma Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera - The Globe and Mail
Multiple Myeloma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharma - Barchart.com
The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie - TradingView
Are Wall Street Analysts Predicting AbbVie Stock Will Climb Or Sink? - Barchart.com
If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
AbbVie to Present at the Bank of America Securities Healthcare C - GuruFocus
JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects? - TradingView
AbbVie to Present at the Bank of America Securities Healthcare Conference - Yahoo Finance
AbbVie (ABBV) Set for Gains with Medicare Policy Shift | ABBV St - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. LawsuitABBV - marketscreener.com
ChatGPT Stock Advice: AbbVie Inc. (ABBV) Among Top Stock Recommendations - Yahoo Finance
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security ConcernsiShares Biotechnology ETF (NASDAQ:IBB), AbbVie (NYSE:ABBV) - Benzinga
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for InvestorsContact The Gross Law Firm - marketscreener.com
AbbVie Inc. (ABBV) Stock Analysis: Navigating Growth with a 6.15% Upside Potential - DirectorsTalk Interviews
Viral Conjunctivitis Drugs Market Overall Study Report - openPR.com
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - Yahoo Finance
Allergan Aesthetics Boosts Women Entrepreneurs with BOTOX Cosmetic Initiative (ABBV) - GuruFocus
Fund Update: SATURNA CAPITAL CORP added 40,521 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Conta - GuruFocus
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your RightsABBV - marketscreener.com
BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project" - AbbVie News Center
AbbVie shares snap seven-session gaining streak - MSN
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV - marketscreener.com
Class Action Filed Against Cerevel Therapeutics Holdings, - GlobeNewswire
PTAB Axes AbbVie Unit's Cancer Drug Patent As Invalid - Law360
Androgen Drugs Market Detailed in New Research Report By 2032 | AbbVie Inc.,Endo International plc - openPR.com
FDA approves AbbVie’s upadacitinib for giant cell arteritis - Yahoo Finance
AbbVie secures FDA approval for Rinvoq to treat giant cell arteritis - World Pharmaceutical Frontiers
In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis - insights.citeline.com
AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis - Benzinga
Why AbbVie Stock Topped the Market Today - MSN
AbbVie (NYSE:ABBV) Receives FDA Approval For RINVOQ In Treating Giant Cell Arteritis - Yahoo Finance
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga
Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next? - Benzinga
AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News
AbbVie Says Rinvoq Medication Gets FDA Approval to Treat Giant Cell Arteritis - marketscreener.com
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
AbbVie (ABBV) Target Price Increased Following Strong Quarterly Results | ABBV Stock News - GuruFocus
FDA Approval for AbbVie's Rinvoq (ABBV) in Treating Giant Cell A - GuruFocus
RINVOQ® Receives U.S. FDA Approval for Giant Cell Arteritis - Investing News Network
Guggenheim Adjusts AbbVie Price Target to $216 From $214, Maintains Buy Rating - marketscreener.com
0.93%
1.42%
大文字化:
|
ボリューム (24 時間):